NewsRx

Search our medical news database

Elite Pharmaceuticals, Inc.

Reports from Elite Pharmaceuticals, Inc., detail the recent activities

Published in Lab Business Week, September 23rd, 2007

Reports from Elite Pharmaceuticals, Inc., detail the recent activities.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Elite Pharmaceuticals, Inc.

Report 1: Elite Pharmaceuticals, Inc. (AMEX: ELI) provided an update on the progress of the Company at the annual shareholders meeting on June 26, 2007. A review of recent key accomplishments and a product pipeline status are provided below.

Abuse Resistant Oxycodone - ELI-216

The Company continues to advance ELI-216 forward in its developmental program. This product is a patent-pending opioid abuse deterrent...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook